Omicron-specific Sinopharm, Sinovac COVID vaccine candidates cleared for clinical trial

COVID-19 vaccine candidates developed by a Sinopharm subsidiary and Sinovac Biotech (SVA.O) to target the Omicron variant were approved for clinical trials in Hong Kong, the companies said on Saturday. Scientists worldwide are racing to study upgraded injections against Omicron, as data indicated that antibodies elicited by vaccines based on older strains show weaker activity to neutralise the highly transmissible variant.